FDA Approves Bizengri for NSCLC, Pancreatic Cancer ...Middle East

News by : (Medscape) -
The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Bizengri for NSCLC, Pancreatic Cancer )

Also on site :

Most Viewed News
جديد الاخبار